Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

International Journal of Clinical Oncology

Volumn 17, Issue 6, 2012, Pages 584-589

  Yoshida, Chikashi ^a   Fletcher, Linda ^b   Ohashi, Kazuteru ^c   Wakita, Hisashi ^d   Kumagai, Takashi ^e   Shiseki, Masayuki ^f   Matsuei, Kousei ^g   Inokuchi, Koiti ^h   Hatta, Yoshihiro ⁱ   Shirasugi, Yukari ^j   Yamaguchi, Toshikazu ^k   Sakamoto, Junichi ^l   Branford, Susan ^b   Sakamaki, Hisashi ^c  

^a NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d NARITA RED CROSS HOSPITAL   (Japan)

^e Ohme Municipal General Hospital   (Japan)

^f TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^g Kameda General Hospital   (Japan)

^h NIPPON MEDICAL SCHOOL   (Japan)

ⁱ NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k Biomedical Research Laboratories   (Japan)

^l NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

BCR ABL; Chronic myeloid leukemia; Conversion factor; International scale; Real time quantitative PCR

Indexed keywords

BCR ABL PROTEIN; DASATINIB;

ARTICLE; BCR ABL GENE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CONVERSION FACTOR; GENE CONVERSION; GENE DOSAGE; HUMAN; INTERNATIONAL SCALE; JAPAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

FUSION PROTEINS, BCR-ABL; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84880700401     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0328-x     Document Type: Article

References (20)

1. Goldman JM, Melo JV (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464
2. Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051
3. Deininger M, O'Brien SG, Guilhot F et al (2009) International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH annual meeting abstracts 114:1126
4. Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432
5. Hughes TP, Hochhaus A, Branford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765
6. Mensink E, van de Locht A, Schattenberg A et al (1998) Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102:768-774
7. Branford S, Hughes TP, Rudzki Z (1999) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107:587-599
8. Zhang T, Grenier S, Nwachukwu B et al (2007) Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 9:421-430
9. Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37
10. Paschka P, Branford S, Lorentz C et al (2004) Comparison of "log reduction from median pretherapeutic value" vs ratio BCR-ABL/ABL to express the therapeutic response in CML patients. ASH annual meeting abstracts 104:1013
11. Branford S, Fletcher L, Cross NC et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112:3330-3338
12. Rulcova J, Zmekova V, Zemanova Z et al (2007) The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 31:483-491
13. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
14. Langabeer SE, Gale RE, Harvey RC et al (2002) Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 16:393-399
15. Yagasaki F, Niwa T, Abe A et al (2009) Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki 50:481-487
16. Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444
17. Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035
18. Cross NC, Hughes TP, Hochhaus A et al (2008) International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 32:505-506
19. Müller MC, Munjal U, Erben P et al Stability of conversion factors for BCR-ABL monitoring - implications for the frequency of validation rounds. ASH annual meeting abstracts 116:893
20. White HE, Matejtschuk P, Rigsby P et al (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116:e111-e117